Intensity Therapeutics in the News

Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. In this video, she speaks about the ASCO 2022 Abstract –  Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).

Matthew A. Ingham, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons speaks about Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting.

Intensity Therapeutics founder and the inventor of Intensity’s DfuseRx platform technology, Lew Bender, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors. This innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.

BioBoss host John Simboli interviewed Intensity Therapeutics’ CEO, Lewis H. Bender in March of 2020. The two discussed the challenges facing a small company developing a unique approach to treating cancer, leadership, partnerships, the potential benefits of the new therapy and the risks & fears that entrepreneurs face when starting a biotech company.

Intensity Therapeutics would like to change the way cancer patients are treated. Treatments such as chemotherapy and radiation impact a patient’s entire body, administering toxic side-effects throughout their system.

Lewis Bender, CEO of a Connecticut startup called Intensity Therapeutics, feels compelled to cure cancer. “I had friends dying of cancer when I was in my 50s,” Bender said. “I had an idea…”

[pdf-embedder url=”https://intensitytherapeutics.com/wp-content/uploads/2019/08/PharmaVOICE-finished-article.pdf” title=”PharmaVOICE finished …

Starting in his basement, Lew and his team have created unique cancer penetrating drugs that kill tumors and boost immunity via direct injection, with minimal side effects.

Intensity is developing cancer therapies that are delivered directly into tumors, but also stimulate the innate immune system to address the more systemic effects of cancer. We spoke to Lewis Bender, CEO of Intensity, about the company’s platform technology, how it enlists the innate immune system in the battle against cancer, and the thinking behind the company’s approach.

In cancer treatment, chemotherapy and immunotherapy are often seen as completely separate, if complementary, categories of treatments. A tiny biotech out of Westport, CT now wants to shake up that paradigm — and has just raised $6.5 million to do so.

A Westport biotechnology company is looking to redefine what it means to be cured of cancer, developing a treatment that essentially trains the immune system to recognize diseased cells and fight back any recurrence. Intensity Therapeutics began clinical trials this year to test the safety of its treatment, an injection of a drug called INT230-6 directly into a tumor.

Westport’s Intensity Therapeutics gains ground with potential game changing cancer treatment. Armed with a pair of U.S. patents and some $13 million in investments, Intensity Therapeutics Inc. in Westport has started clinical trials on what its founder maintains could be a game-changer in the treatment of cancer.

Intensity Therapeutics said today that the 1st patient was treated in a Phase I/II trial of its intratumorally-administered cancer therapy, INT230-6. The company’s plans to evaluate the safety of its cancer-killing agent in patients with tumors that are treated at the surface of the skin, including breast cancer and melanoma.

Intensity Therapeutics Inc. got its start when Lewis H. Bender, then the CEO of Interleukin Genetics Inc., pondered the treatment failures in checkpoint inhibitors. “I thought, ‘There’s a steering wheel missing,’” he recalls. The key would be to kill tumor cells, but in a way that left them and their cell surface proteins more or less intact.

Many cancer treatments have achieved cures in mice only to fail in humans. Intensity Therapeutics has studied these failed challengers, and it may have learned why they failed to go the distance.

Venture investor Len Batterson says new crowdfunding rules will widen the pool of sophisticated investors, too.

Intensity Therapeutics has raised USD 1.5m of its planned USD 9m target for its lead preclinical candidate, an intratumoral chemotherapy, said CEO Lewis Bender. By the end of 3Q14, the firm plans to finalize CMOs and CROs for clinical studies, he noted.

Intensity Therapeutics Inc. is developing what could become the first intratumoral chemotherapeutics to achieve better efficacy than systemic chemo by using a formulation technology that enables passive diffusion into tumor cells.